CLINICAL PHARMACOLOGY OF MINERALOCORTICOID RECEPTOR ANTAGONISTS AND THEIR USE IN TREATMENT OF INTERNAL DISEASE PATHOLOGY
Keywords:
aldosterone, mineralocorticoid receptors, MKRA, spironolactone, eplerenone, ezaxerenone, finerenone.Abstract
The purpose of this article is to summarize research data on the use of MKRA in various pathologies. Information about aldosterone and mineralocorticoid receptors is summarized. Also, the clinical pharmacology of MKRA, i.e. classification, mechanism of action, pharmacodynamic effects, pharmacokinetic parameters, side effects, indications and contraindications, was given complete information
References
Simpson S.A., Tait J.F., Bush I.E. Secretion of a salt-retaining hormone by the mammalian adrenal cortex // Lancet. 1952. V. 2.P. 226–228.А.Э.
Hermidorff MM, de Assis LV, Isoldi MC. Genomic and rapid effects of aldosterone: what we know and do not know thus far. Heart Fail Rev. 2017;22(1):65-89. DOI:10.1007/s10741-016-9591-2.
Mihailidou AS, Funder JW. Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 2005; 70 (5–7): 347–51.
KarpovYA. Eplerenone: improvement of prognosis in patients with chronic heart failure of ischemic etiology. Atmosfera. Novosti kardiologii. 2014;(2):28-37. (In Russ.)
Alimova E.E., Eremina Yu.N. The evolution of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Consilium Medicum. 2017; 19 (10): 60–65. DOI: 10.26442/2075-1753_19.10.60-65.
Leonova M.V., Alimova E.E., Eremina Yu.N. The evolution of mineralocorticoid receptor antagonists: spironolactone and eplerenone. Consilium Medicum. 2017; 19 (10): 60–65. DOI: 10.26442/2075-1753_19.10.60-65.
Kagawa C.M., Sturtevant F.M., Van Arman C.G. Pharmacology of a new steroid that blocks salt activity of aldosterone and desoxycorticosterone. J Pharmacol Exp Ther. 19 59; 126(2):123-30.
Ferrario CM. Cardiac remodelling and RAS inhibition. Ther Adv
Cardiovasc Dis. 2016;10(3):162-71.
Kim SK, McCurley AT, DuPont JJ, et al. Smooth Muscle CellMineralocorticoid Receptor as a Mediator of Cardiovascular Stiffness With Aging. Hypertension. 2018;71(4):609-21.
DOI:10.1161/HYPERTENSIONAHA.117.10437
Kotfis K, Lechowicz K, Drożdżal S, et al. COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection. Pharmaceuticals (Basel). 2021;14(1):71. DOI:10.3390/ph14010071.
Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114. DOI:10.15252/embj.20105114.
Clinckemalie L, Spans L, Dubois V, et al. Androgen regulation of the TMPRSS2 gene and the effect of a SNP in an androgen response element. Mol Endocrinol. 2013;27:2028-40. DOI:10.1210/me.2013-109.
Lieber GB, Fernandez X, Mingo GG, et al. Mineralocorticoid receptor
antagonists attenuate pulmonary inflammation and bleomycin-evoked
fibrosis in rodent models. Eur J Pharmacol. 2013;718(1-3):290-8.
DOI:10.1016/j.ejphar.2013.08.019.
Zhou H, Xi D, Liu J, et al. Spirolactone provides protection from
renal fibrosis by inhibiting the endothelial-mesenchymal transition
in isoprenaline-induced heart failure in rats. Drug Des Devel Ther.
;10:1581-8. DOI:10.2147/DDDT.S100095 ТЕРАПЕВТИЧЕСКИЙ АРХИВ. 2021; 93 (9): 1132–1137.
Mackenzie IS, Morant SV, Wei L, et al. Spironolactone use and risk
of incident cancers: a retrospective, matched cohort study. Br J Clin
Pharmacol. 2017;83(3):653-63. DOI:10.1111/bcp.13152.
Biggar Robert J., Andersen Elisabeth W, Wohlfahrt Jan, Melbye Mads. Spironolactone use and the risk of breast and gynecologic cancers. Cancer Epidemiol. 2013 Dec;37(6):870-5. doi: 10.1016/j.canep.2013.10.004. Epub 2013 Nov 1.
de Gasparo M, Joss U, Ramjoué HP, Whitebread SE, Haenni H, Schenkel L, Kraehenbuehl C, Biollaz M, Grob J & Schmidlin J 1987 Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. Journal of Pharmacology and Experimental Therapeutics 240 650–656.
Rubenko OA, Duplyakov DV. Efficiency of therapy with spironolactone in patients with chronic heart failure. Cardiology: News, Opinions, Training. 2018;6(2):22-28. (In Russ.) https://doi.org/10.24411/2309-1908-2018-12003.
Vatutin NT, Kravchenko IN. The effect of aldosterone antagonists on the electrophysiological parameters in recurrence atrial fibrillation. Medicinskii vestnik Yuga Rossii. 2016;3:39-45. (In Russ.)
Paul A. Heidenreich, Biykem Bozkurt, David Aguilar, Larry A. Allen, Joni J. Byun, Monica M. Colvin, Anita Deswal, Mark H. Drazner, Shannon M. Dunlay, Linda R. Evers, James C. Fang, Savitri E. Fedson, Gregg C. Fonarow, Salim S. Hayek, Adrian F. Hernandez, Prateeti Khazanie, Michelle M. Kittleson, Christopher S. Lee, Mark S. Link, Carmelo A. Milano, … See all authors. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. 2022;145:e895–e1032.
Bakris George L., M.D., Rajiv Agarwal, M.D., Stefan D. Anker, M.D., Ph.D., Bertram Pitt, M.D., Luis M. Ruilope, M.D., Peter Rossing, M.D., Peter Kolkhof, Ph.D., Christina Nowack, M.D., Patrick Schloemer, Ph.D., Amer Joseph, M.B. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med 2020; 383:2219-2229
DOI: 10.1056/NEJMoa2025845.
Bertram Pitt, M.D., Gerasimos Filippatos, M.D., Rajiv Agarwal et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med 2021; 385:2252-2263 DOI: 10.1056/NEJMoa2110956
Статья поступила в редакцию 10.05.2024; одобрена после рецензирования 21.06.2024; принята к публикации 29.06.2024.
The article was submitted 10.05.2024; approved after reviewing 21.06.2024; accepted for publication 29.06.2024.
Информация об авторах:
Саидова Шахноза Ариповна -т.ф.н., Тошкент тиббиёт академияси, клиник фармакология кафедраси катта укитувчиси ShahnozaAripovna@gmail.com https://orcid.org/0000-0001-6168-714X
Мусаева Лола Жураевна -т.ф.н., Тошкент тиббиёт академияси, клиник фармакология кафедраси катта укитувчиси lolahon2010@mail.ru https://orcid.org/0000-0002-2754-3609
Пулатова Наргиза Ихсановна -т.ф.д., Тошкент тиббиёт академияси, клиник фармакология кафедраси доценти nargiza.pulatova1984@gmail.com https://orcid.org/0000-0001-7178-6416
Пулатова Дурдона Бахадировна -т.ф.н., Тошкент тиббиёт академияси, клиник фармакология кафедраси доценти d.b.pulatova@gmail.com https://orcid.org/0000-0003-3438-4332
Абдусаматова Дилором Зиявуддиновна -т.ф.н., Тошкент тиббиёт академияси, клиник фармакология кафедраси катта укитувчиси d.z.abdusamatova@gmail.com https://orcid.org/0000-0001-9231-3992
Авазова Гулчехра Нуриллаевна- Тошкент тиббиёт академияси, клиник фармакология кафедраси ассистенти g.nurillaevna@mail.ru https://orcid.org/0000-0001-7178-6416
Источники финансирования: Работа не имела специального финансирования.
Конфликт интересов: Авторы декларируют отсутствие явных и потенциальных конфликтов интересов, связанных с публикацией настоящей статьи.
Вклад авторов:
Саидова Ш.А. — идеологическая концепция работы, написание текста; редактирование статьи;
Мусаева Л.Ж. — сбор и анализ источников литературы, редактирование статьи;
Пулатова Н.И.- написание текста; редактирование статьи;
Пулатова Д.. - сбор и анализ источников литературы, написание текста.
Абдусаматова Д.З.- написание текста; редактирование статьи;
Авзова Г.Н-— сбор и анализ источников литературы, написание текста.
Sources of funding: The work did not receive any specific funding.
Conflict of interest: The authors declare no explicit or potential conflicts of interest associated with the publication of this article.
Contribution of the authors:
Saidova Sh.A. — ideological concept of the work, writing the text; editing the article;
Musayeva L.J. — collection and analysis of literature sources, editing the article;
Pulatova N.I.- writing the text; editing the article;
Pulatova D.B.- collection and analysis of literature sources, writing the text.
Abdusamatova D.Z.- writing the text; editing the article;
Avazova G.N.- collection and analysis of literature sources, writing the text.
